17 August 2020: Clinical Research
Evaluation of Ovarian Tumors with Multidetector Computed Tomography and Tumor Markers: Differentiation of Stage I Serous Borderline Tumors and Stage I Serous Malignant Tumors Presenting as Solid-Cystic Mass
Xin-Ping Yu 1BCE , Ying Liu 2C , Jin-Wen Jiao 1D , Hong-Juan Yang 1B , Rui-Jing Wang 1D , Shuai Zhang 3ACF*DOI: 10.12659/MSM.924497
Med Sci Monit 2020; 26:e924497
Table 3 Comparison of quantitative measures of SBOTs and SMOTs.
| Parameter | SBOTs (n=48) | SMOTs (n=54) | P value |
|---|---|---|---|
| CA125 (U/mL) | 130.3 (40.1–326.1) | 328.8 (66.5–1270.5) | 0.005 |
| CA19-9 (U/mL) | 15.9 (10.4–24.9) | 18.3 (9.0–41.9) | 0.573 |
| CEA (ng/mL) | 1.2 (0.5–1.8) | 1.4 (0.9–2.3) | 0.059 |
| HE4 (pmol/L) | 74.6 (64.1–95.1) | 123.3 (73.4–255.8) | |
| Arterial phases attenuation value (Hu) | 54.5 (48.1–59.2) | 53.6 (46.8–56.8) | 0.163 |
| Venous phases attenuation value (Hu) | 60.1 (56.6–65.6) | 57.5 (55.0–64.9) | 0.056 |
| Equilibrium phase attenuation value (Hu) | 66.5 (61.5–73.5) | 68.4 (59.4–68.9) | 0.062 |
| Size (mm) | 79.1 (56.8–109.4) | 80.9 (60.8–112.6) | 0.580 |
| Maximum thickness of wall (mm) | 2.6 (1.8–3.6) | 3.45 (2.8–3.8) | 0.001 |
| Maximum thickness of septa (mm) | 2.6 (2.3–3.6) | 3.5 (2.8–3.9) | 0.002 |
| Maximum diameter of solid component (mm) | 31.5 (25.4–39.8) | 43.5 (31.6–51.0) | |
| Data are presented as the median (inter-quartile range). SBOTs – serous borderline ovarian tumors; SMOTs – serous malignant ovarian tumors; CA125 – serum cancer antigen 125; CA19-9 – carbohydrate antigen 19-9; CEA – carcinoembryonic antigen; HE4 – human epididymis protein 4. | |||